Skip to main content
OpenTrials
Completed

NCT Number: NCT00856908

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type II Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

30 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Site

Chula Vista, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • type II diabetes patients, female with non child-bearing potential
  • Subjects with T2DM diagnosis for at least one year, treated with insulin alone or insulin in combination with other anti-diabetic drugs. Subjects must have been treated with insulin the last 3 months prior to enrolment (screening)
  • HbA1c <11% at enrolment (screening) (HbA1c value according to international Diabetes Control and Complications Trial [DCCT] standard).
  • FPG in the range of 7.0 to 13.0 mmol/L (126 to 234 mg/dL)

Exclusion criteria

  • History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
  • Use of glitazones, warfarin, amiodarone within 3 months prior to enrolment (screening) and use of potent CYP450 inhibitors, eg, ketoconazole and macrolide antibiotics within 14 days before randomisation.
  • Any clinically significant abnormality identified on physical examination, laboratory tests or ECG, which in the judgment of the investigator would compromise the patients' safety or successful participation in the clinical study.

Treatment and study plan

AZD1656

Drug

Tolerable dose given twice daily

Placebo

Drug

Tolerable dose given twice daily

Primary outcomes

  1. Systolic Blood Pressure, Change From Baseline to End of Treatment

    Time frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period

  2. Diastolic Blood Pressure, Change From Baseline to End of Treatment

    Time frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period

  3. Pulse, Change From Baseline to End of Treatment

    Time frame: Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period

  4. Weight, Change From Baseline to End of Treatment

    Time frame: Baseline is the day before first dose, end of treatment is last day of treatment

  5. Clinically Relevant Change of Laboratory Variables

    Time frame: Measured regularly from day before first dose to day after last dose

    Number of participants with clinically relevant change of laboratory variables (clinical chemistry, haematology and urinalysis parameters

Secondary outcomes

  1. Area Under the Plasma Concentration vs Time Curve (AUC0-24) of AZD1656

    Time frame: Measured last day of treatment

    Dose-adjusted to a total daily dose of 100 mg due to titrated doses

  2. Maximum Plasma Concentration of AZD1656

    Time frame: Measured following the morning dose last day of treatment

    Dose-adjusted to a morning dose of 50 mg due to titrated doses

  3. Time to Reach Maximum Plasma Concentration of AZD1656

    Time frame: Measured last day of treatment

  4. Terminal Elimination Half-life of AZD1656

    Time frame: Measured following the evening dose last day of treatment

  5. Apparent Oral Clearance of AZD1656

    Time frame: Measured last day of treatment

  6. P-Glucose (AUC0-24)/24, Change From Baseline to End of Treatment

    Time frame: Baseline is the day before first dose, end of treatment is last day of treatment

    Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent. Changes in percent have been obtained by subtraction by 100.

  7. S-Insulin (AUC0-24)/24, Change From Baseline to End of Treatment

    Time frame: Baseline is the day before first dose, end of treatment is last day of treatment

    Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent. Changes in percent have been obtained by subtraction by 100

  8. S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment

    Time frame: Baseline is the day before first dose, end of treatment is last day of treatment

    Log ratio (End of treatment/Baseline) has been analysed in an ANCOVA model, using treatment as fixed factor and log(Baseline) as covariate. Resulting estimates have been back-transformed from the log-scale and then multiplied by 100 to obtain the relative ratio (end of treatment/placebo) in percent. Changes in percent have been obtained by subtraction by 100.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Mar 6, 2009
Registry last updated
Dec 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.